Regeneron Pharmaceuticals Stock News

Regeneron is a powerhouse in drug discovery with a promising pipeline and innovative treatments. Revenues are stable with flagship drugs like Eylea providing a revenue cushion and Dupixent driving growth. The next-generation drugs in oncology and obesity are the next potential wave of growth, with even more exciting treatments following them.

Regeneron shares have recently crossed over the $1,000 price point. The company has achieved significant growth and there could more to come.

Regeneron's Q2 2024 revenue grew 12% year-over-year, reaching $3.55 billion. Dupixent's global net sales increased by 27% to $3.56 billion, driving overall revenue growth. Eylea HD mitigated market share losses by earning $304 million and stabilizing the Eylea franchise.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Q2 2024 Earnings Conference Call August 1, 2024 8:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relations and Strategic Analysis Leonard Schleifer - Board Co-Chair, Co-Founder, President and Chief Executive Officer George Yancopoulos - Board Co-Chair, Co-Founder, President and Chief Scientific Officer Marion McCourt - E...

Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.

A strong second-quarter performance lifted the already extended shares of the New York-based drugmaker Regeneron.

TARRYTOWN, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) --  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2024 and provided a business update.

TARRYTOWN, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 12th annual Regeneron Prize for Creative Innovation (the Regeneron Prize), an award that recognizes, celebrates and rewards outstanding talent and creativity from early-career scientists in biomedical research.